NICE changes mind; recommends Novartis’ asthma drug

Hannah Blake


The UK’s National Institute for Health and Clinical Excellence (NICE) has decided to go ahead and recommend Novartis’ Xolair as an option for treating severe, persistent allergic asthma in adults, adolescants and children. This move comes as a complete u-turn for the Committee, who withdrew its recommendation of Novartis’ drug back in November 2012.

NICE’s new decision to recommend Xolair (omalizumab) follows additional analyses and submission of a patient access scheme (PAS) by Novartis.

“NICE is aware that severe, persistent allergic asthma can have a significant effect on a person’s life. We are therefore pleased to now be able to recommend omalizumab as an effective therapy for adults, adolescents and children with this condition in final draft guidance, with the discount agreed in the patient access scheme submitted by the manufacturer.”

Professor Carole Longson, Health Technology Evaluation Centre Director at NICE.

The final draft guidance can now be found from Thursday 7 March on the NICE website, but will not be issued as final guidance to the NHS yet – the expected date for this is during April 2013.


Related news:

NICE backs Novartis asthma drug in fresh U-turn (Reuters)

Reference links:

NICE press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.